PMID- 27635609
OWN - NLM
STAT- MEDLINE
DCOM- 20170113
LR  - 20181202
IS  - 1997-7298 (Print)
IS  - 1997-7298 (Linking)
VI  - 116
IP  - 8
DP  - 2016
TI  - [Effect of antioxidant therapy on neurotrophins and processes of rehabilitation 
      after stroke].
PG  - 36-39
LID - 10.17116/jnevro20161168136-39 [doi]
AB  - The aim of the research was to study the effect of the inclusion in the scheme 
      cytoflavin patient care during the recovery period of ischemic stroke in the 
      neuropsychological changes in the status and content of neurotrophins in serum. 
      For this purpose we surveyed 52 patients who underwent a first ischemic stroke 
      (29 women and 23 men) aged 52-74 years. Patients were divided into 2 groups: 
      primary (25 patients) received in addition to basic therapy cytoflavin: 
      intravenously at 20 ml per 400 ml of 5% glucose solution, 1 time a day for 10 
      days, then into 2 tablets 2 times a day for half an hour before food for a month, 
      and the comparison group (27 patients) who received standard treatment. The 
      control group consisted of 12 healthy people. In addition to standard clinical 
      and laboratory tests were carried out a comprehensive neuropsychological study 
      and evaluation of the data on the scale NIHSS, Bartell, Beck, Spielberger-Hanin, 
      test <<frontal dysfunction of the battery>> and the Mini-Mental State Examination. 
      Furthermore, determination carried neurotrophic factors: nerve growth factor 
      (NGF) and brain-derived neurotrophic factor brain (BDNF). The study was conducted 
      in the dynamics: before treatment and 2 months after treatment. Patients in the 
      recovery period of the first ischemic stroke revealed moderate manifestations of 
      neuropsychological disorders status and reduction of neurotrophic factors. 
      Inclusion in cytoflavin scheme increased the efficiency of the treatment, which 
      was manifested in a more pronounced when compared with the results of basic 
      therapy, positive dynamics of neurological symptoms and improved cognitive 
      function, accompanied by an increase in BDNF levels. The data on the efficacy and 
      safety allow us to recommend its inclusion in the scheme of treatment of patients 
      in the recovery period after the first carotid ischemic stroke.
FAU - Karakulova, Y V
AU  - Karakulova YV
AD  - Vagner Perm State Medical University, Perm, Russia.
FAU - Selyanina, N V
AU  - Selyanina NV
AD  - Vagner Perm State Medical University, Perm, Russia.
FAU - Zhelnin, A V
AU  - Zhelnin AV
AD  - Perm Krai 'Perm Regional Clinical Hospital', Perm, Russia.
FAU - Filimonova, T A
AU  - Filimonova TA
AD  - Perm Krai 'Perm Regional Clinical Hospital', Perm, Russia.
FAU - Cepilov, S V
AU  - Cepilov SV
AD  - Resort 'Kluchi', Perm Krai, Russia.
LA  - rus
PT  - Controlled Clinical Trial
PT  - Journal Article
TT  - Vliyanie antioksidantnoi terapii na neirotrofiny i protsessy reabilitatsii posle 
      insul'ta.
PL  - Russia (Federation)
TA  - Zh Nevrol Psikhiatr Im S S Korsakova
JT  - Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
JID - 9712194
RN  - 0 (Antioxidants)
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Drug Combinations)
RN  - 0 (Succinates)
RN  - 0 (cytoflavin)
RN  - 25X51I8RD4 (Niacinamide)
RN  - 7171WSG8A2 (BDNF protein, human)
RN  - 7N464URE7E (Flavin Mononucleotide)
RN  - 86-04-4 (Inosine Diphosphate)
RN  - 9061-61-4 (Nerve Growth Factor)
SB  - IM
MH  - Aged
MH  - Antioxidants/*therapeutic use
MH  - Brain-Derived Neurotrophic Factor/*blood
MH  - Drug Combinations
MH  - Female
MH  - Flavin Mononucleotide/*therapeutic use
MH  - Humans
MH  - Inosine Diphosphate/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Nerve Growth Factor/*blood
MH  - Niacinamide/*therapeutic use
MH  - Stroke/blood/*drug therapy
MH  - Stroke Rehabilitation/*methods
MH  - Succinates/*therapeutic use
MH  - Treatment Outcome
EDAT- 2016/09/17 06:00
MHDA- 2017/01/14 06:00
CRDT- 2016/09/17 06:00
PHST- 2016/09/17 06:00 [entrez]
PHST- 2016/09/17 06:00 [pubmed]
PHST- 2017/01/14 06:00 [medline]
AID - 10.17116/jnevro20161168136-39 [doi]
PST - ppublish
SO  - Zh Nevrol Psikhiatr Im S S Korsakova. 2016;116(8):36-39. doi: 
      10.17116/jnevro20161168136-39.